
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Health care is at the top of the legislative agenda this month as Congressional committees get to work on the nitty-gritty of the federal budget.






